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Abstract 
A novel TBL1XR1/MECOM fusion was identified 
in a patient with acute undifferentiated leukemia. 
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Identity 
del(3)(q26.2q26.3) TBL1XR1/MECOM 
Clinics and pathology 
Disease 
Acute undifferentiated leukaemia (classified in acute 
leukaemias of ambiguous lineage) 
Phenotype/cell stem origin 
This leukemia was CD34+high, CD38+ and 
CD117+/- but negative for all lineage specific 
markers (cMPO-, CD13-, CD33-, CD7-, cCD3-, 
cCD79a-, CD19-, cCD22- cCD79a-). 
Epidemiology 
Only one case described, a 44-year-old-man (present 
report) 
Cytology 
Undifferentiated blasts, without criteria specific for 
either lineage (myeloid or lymphoid) 
Treatment 
The patient was treated according to the GRAALL- 
2014 protocol for adult acute lymphoblastic 
leukemia including induction, salvage course, then 
consolidation blocks and allo-HSCT transplantation. 
Cytogenetics 
Note 
No abnormality detected on conventional karyotype: 
46,XY[20] 
Probes 
XL MECOM D-5059-100-OG 
Genes involved and 
proteins 
MECOM (Ecotropic Viral Integration 
Site 1 (EVI1) and Myelodysplasic 
Syndrome 1 (MDS1/EVI1)) 
Location 
3q26.2 
Note 
MECOM is also known as EV1 or PRDM3. 
MECOM means MDS and EVI1 complex locus. 
DNA/RNA 
EVI1 locus spans approximately 65 kb and contains 
16 exons.  
MDS1 locus spans approximately 500 kb and 
contains 4 exons.  
The MDS1/EV1 transcript results from intergenic 
splicing of the second exon of MDS1 (telomere) to 
the second exon of EVI1 (centromere) 
TBL1XR1/MECOM fusion Abdo C, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2019; 23(3) 66 
 
 
 
 
FISH using a locus specific break-apart MECOM 3q26 probe (Metasystem XL D-5059-100-OG) confirmed the deletion at 3q26.2 
locus telomeric to MECOM (loss of green signal). 
Protein 
MDS1/EVI1 protein contains a positive regulator 
domain (PR-domain) acting as a tumor-suppressor,   
a repression domain between two sets of several zinc 
finger motifs, and an acidic domain at its C-terminus. 
It is a nuclear transcriptional regulator involved in 
differentiation, proliferation and maintenance of 
hematopoietic stem cells. Deregulation of the proto-
oncogene MECOM by the 3q rearrangements (inv3 
or t(3;3)) reposition a distal GATA2 enhancer, 
inducing an aberrant expression of EVI1 and 
conferring GATA2 fonctional haploinsufficiency 
(Gröschel et al, 2014). This mechanism is implicated 
in leukemogenesis of MDS/ AML with an extremely 
poor treatment outcome. 
TBL1XR1 (Transducin beta like 1 X-
linked receptor 1) 
Location 
3q26.32 
Note 
TBL1XR1 is also known as MRD41 
 
DNA/RNA 
TBL1XR1 locus contains 18 exons.  
It is a member of the WD40 repeat-containing gene 
family 
Protein 
The TBL1XR1 gene encodes a protein of 514 amino 
acids, which is a component of both N-CoR (nuclear 
receptor corepressor) and SMRT (silencing mediator 
of retinoid acid and thyroid hormone receptor) 
repressor complexes, which targeting nuclear 
receptor to repress transcription. TBL1XR1 is also 
required for transcriptional activation by many 
transcription factors (Li et al, 2015). The protein 
contains a LisH domain (Lis1 homology domain) 
and a F-box like domain in its N-terminal region, and 
8 WD40 repeats at the carboxy-terminus. It seems to 
play a role in the maintenance of hematopoietic stem 
cells (Li et al, 2015). TBL1XR1 mutations and 
rearrangements have been described in several 
lymphoid malignancies including diffuse large B cell 
lymphoma, acute lymphoblastic leukemia and acute 
promyelocytic leukemia (Heinen et al, 2016). 
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Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5'TBL1XR1-3'MECOM. TBL1XR1 exon 7 fused 
in-frame with MECOM exon 9 or 10. 
Detection 
RT-PCR using MECOM and TBL1XR1 primers. 
Fusion protein 
Schematic representations of TBL1XR1 and MECOM 
proteins and TBL1XR1/MECOM putative fusion proteins. 
Description 
The TBL1XR1/MECOM rearrangement may result 
in a putative hybrid protein containing the N-
terminal portion (234 first aminoacids) of TBL1XR1 
with its LisH, F-box and part of WD repeat domains 
and the C-terminal portion (381 last aminoacids) of 
MECOM retaining one set of zinc finger motif and 
the acidic domain. 
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